Search Results - "Gupta, I. V."

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA‐SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐5 STUDY by Nooka, A., Lonial, S., Grosicki, S., Hus, M., Song, K., Facon, T., Callander, N. S., Ribrag, V., Uttervall, K., Quach, H., Vorobyev, V., Min, C.‐K., Cheng, S., Smith, L. M., Yu, J., Collingwood, T., Holkova, B., Kremer, B. E., Gupta, I. V., Richardson, P. G., Minnema, M. C.

Get full text

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C.-K., Janowski, W., Abdallah, A.-O., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez-Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., Hus, M.

Get full text

Adsorption studies on the removal of coloring agent phenol red from wastewater using waste materials as adsorbents by Mittal, Alok, Kaur, Dipika, Malviya, Arti, Mittal, Jyoti, Gupta, V.K.

“…Effect of pH on the uptake of phenol red by bottom ash and deoiled soya. Bottom ash, a waste of thermal power plants, and deoiled soya, an agricultural waste…”
Get full text

CD11b agonists offer a novel approach for treating lupus nephritis by VILLANUEVA, VERONICA, LI, XIAOBO, JIMENEZ, VIVIANA, FARIDI, HAFEEZ M., GUPTA, VINEET

“…Lupus nephritis (LN) develops in more than a third of all systemic lupus erythematosus (SLE) patients and is the strongest predictor of morbidity and…”
Get full text

P942: DREAMM‐9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C.‐K., Janowski, W., Abdallah, A.‐O., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez‐Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., Hus, M.

Get full text

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study by Österborg, Anders, Jewell, Roxanne C, Padmanabhan-Iyer, Swami, Kipps, Thomas J, Mayer, Jiří, Stilgenbauer, Stephan, Williams, Cathy D, Hellmann, Andrzej, Furman, Richard R, Robak, Tadeusz, Hillmen, Peter, Trnêný, Marek, Dyer, Martin J S, Piotrowska, Magdalena, Kozak, Tomas, Gupta, Ira V, Phillips, Jennifer L, Goldstein, Nancy, Struemper, Herbert, Losic, Nedjad, Lisby, Steen, Wierda, William G

Get full text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial by Hillmen, Peter, Prof, Robak, Tadeusz, MD, Janssens, Ann, MD, Babu, K Govind, MD, Kloczko, Janusz, MD, Grosicki, Sebastian, MD, Doubek, Michael, MD, Panagiotidis, Panagiotis, MD, Kimby, Eva, MD, Schuh, Anna, MD, Pettitt, Andrew R, MRCPath, Boyd, Thomas, MD, Montillo, Marco, MD, Gupta, Ira V, MD, Wright, Oliver, BSc, Dixon, Iestyn, BSc, Carey, Jodi L, RN BSN, Chang, Chai-Ni, MS, Lisby, Steen, MD, McKeown, Astrid, PhD, Offner, Fritz, MD

“…Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based…”
Get full text

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study by Wierda, William G., Padmanabhan, Swaminathan, Chan, Geoffrey W., Gupta, Ira V., Lisby, Steen, Österborg, Anders

“…Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with…”
Get full text

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients by Österborg, Anders, Wierda, William G., Mayer, Jiří, Hess, Georg, Hillmen, Peter, Schetelig, Johannes, Schuh, Anna, Smolej, Lukáš, Beck, Christian, Dreyfus, Brigitte, Hellman, Andrzej, Kozlowski, Piotr, Pfreundschuh, Michael, Rizzi, Rita, Spacek, Martin, Phillips, Jennifer L., Gupta, Ira V., Williams, Vanessa, Jewell, Roxanne C., Nebot, Noelia, Lisby, Steen, Dyer, Martin J. S.

“…Summary There are limited data on retreatment with monoclonal antibodies (mAb) in patients with chronic lymphocytic leukaemia (CLL). In a pivotal study,…”
Get full text

A Clinical Case of Viral Keratitis by Gupta, Devanshu, Daigavane, Sachin

“…Keratitis is a pathological condition involving inflammation of the cornea. It can be an infectious or non-infectious disease. The causative organisms of…”
Get full text

Clinicopathological Study of Primary Gastrointestinal Lymphoma from a Tertiary Care Hospital in Southern India by Gupta, Kavita, Kudva, Ranjini, Monappa, Vidya, Nikhra, Pawan

“…Introduction: Primary Gastrointestinal Lymphoma (PGIL) is a heterogeneous disease in terms of patient characteristics, site, histologic types and treatment…”
Get full text

PRETREATMENT CHARACTERISTICS CORRELATED WITH OUTCOMES IN PATIENTS WITH FLUDARABINE-REFRACTORY CLL TREATED WITH OFATUMUMAB: FINAL RESPONSE ANALYSIS by Wierda, WG, Gupta, IV, Lisby, S, Osterborg, A

Get full text

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia by Wierda, WG, Kipps, TJ, Mayer, J, Robak, T, Dyer, MJS, Eurman, RR, Hillmen, P, Stilgenbauer, S, Williams, CD, Trneny, M, Cartron, G, Hernandez-Ilizaliturri, FJ, Padmanabhan, S, Chan, GW, Gupta, IV, Gorczyca, MM, Davis, RL, Losic, N, Lisby, S, Osterborg, A

Get full text